Question · asked by 1 review
Methylnaltrexone vs placebo: Adverse events
- Population
- people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
- Intervention
- Methylnaltrexone
- Comparison
- placebo
- Outcome
- Adverse events
Methylnaltrexone may leads to higher adverse events compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Methylnaltrexone vs placebo Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction Methylnaltrexone may leads to higher adverse events compared with placebo (low certainty). Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane Headline outcomes only | RR 1.17 | 3 studies · 518 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Methylnaltrexone vs placebo · people with cancer and people receiving palliative care with opioid‐induced bowel… · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.